Whales with a lot of money to spend have taken a noticeably bullish stance on Gilead Sciences.
Looking at options history for Gilead Sciences GILD we detected 11 trades.
If we consider the specifics of each trade, it is accurate to state that 54% of the investors opened trades with bullish expectations and 36% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $175,223 and 6, calls, for a total amount of $302,880.
Predicted Price Range
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $60.0 to $115.0 for Gilead Sciences over the last 3 months.
Volume & Open Interest Trends
In terms of liquidity and interest, the mean open interest for Gilead Sciences options trades today is 828.82 with a total volume of 4,116.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Gilead Sciences's big money trades within a strike price range of $60.0 to $115.0 over the last 30 days.
Gilead Sciences 30-Day Option Volume & Interest Snapshot
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GILD | CALL | SWEEP | BEARISH | 06/20/25 | $3.4 | $3.3 | $3.3 | $110.00 | $78.2K | 2.2K | 261 |
| GILD | CALL | SWEEP | BULLISH | 04/25/25 | $4.0 | $3.7 | $4.0 | $104.00 | $62.8K | 1.0K | 159 |
| GILD | CALL | TRADE | BULLISH | 05/16/25 | $2.6 | $2.6 | $2.6 | $108.00 | $61.6K | 18 | 241 |
| GILD | PUT | SWEEP | BULLISH | 03/20/26 | $1.2 | $1.03 | $1.06 | $60.00 | $51.5K | 120 | 480 |
| GILD | CALL | SWEEP | BULLISH | 04/25/25 | $1.33 | $1.24 | $1.33 | $108.00 | $39.9K | 155 | 312 |
About Gilead Sciences
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Having examined the options trading patterns of Gilead Sciences, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
Current Position of Gilead Sciences
- Trading volume stands at 3,825,036, with GILD's price up by 0.09%, positioned at $105.6.
- RSI indicators show the stock to be is currently neutral between overbought and oversold.
- Earnings announcement expected in 1 days.
Expert Opinions on Gilead Sciences
In the last month, 2 experts released ratings on this stock with an average target price of $127.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $125. * Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Gilead Sciences with a target price of $130.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Gilead Sciences options trades with real-time alerts from Benzinga Pro.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
